December 2015 in “OPAL (Open@LaTrobe) (La Trobe University)” Oleuropein increases IGF-1 levels in mouse skin.
3 citations
,
December 2019 in “Journal of Cosmetic and Laser Therapy” PRGF treatments increased hair number and thickness in people with hair loss, with more injections leading to better results.
February 2016 in “Evidence Based Women Health Journal (Online)” Women with PCOS had higher SRAGE levels, possibly linked to BMI, not PCOS.
October 2024 in “Journal of the Endocrine Society” Gender-affirming hormone therapy affects metabolism differently based on treatment type.
17 citations
,
August 2001 in “Australasian journal of dermatology” A woman's liver problems improved after she stopped taking spironolactone.
39 citations
,
August 2001 in “Clinical endocrinology” Lean and obese women with PCOS have similar levels of insulin resistance, indicating it's a core aspect of the condition.
45 citations
,
January 2007 in “Journal of Clinical Oncology” Sorafenib may cause hand-foot and stump syndrome, requiring early detection and management.
January 2026 in “BIO Web of Conferences” FGFs have evolved differently across species, affecting skin functions and wound healing.
January 2003 in “Hepatology” Ethanol changes GABAA receptor α4 subunit levels through phosphorylation and neuroactive steroids.
24 citations
,
July 2017 in “Structure” FGF9 controls which receptors it binds to through a process where two FGF9 molecules join, and changes in FGF9 can lead to incorrect receptor activation.
January 2025 in “Haematology International Journal” These ovarian conditions cause high testosterone levels.
32 citations
,
September 2018 in “Clinical Obstetrics and Gynecology” Hormone therapy for transgender females increases the risk of blood clots and requires careful dosing, monitoring, and lifelong management.
25 citations
,
January 2019 in “Annals of Dermatology” Blocking the NOTCH pathway can prevent fibrosis in systemic sclerosis.
February 2026 in “International Journal of Nanomedicine” The system improved diabetic wound healing in rats.
54 citations
,
November 2017 in “Scientific Reports” The study found that certain microRNAs are higher in the cells and lower in the fluid of women with a specific type of polycystic ovary syndrome, and one microRNA could potentially help diagnose the condition.
20 citations
,
June 2019 in “JAAD Case Reports” Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.
2 citations
,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
Some fibroblast growth factors may promote hair growth similarly to minoxidil and could potentially treat hair loss.
November 2017 in “Reactions Weekly” Testosterone undecanoate caused hair loss; finasteride improved it but caused stomach issues for one patient.
4 citations
,
January 2024 in “Allergy” Everyone has an immune response to PPD, but reactions differ, causing tolerance, mild inflammation, or allergy.
29 citations
,
July 2012 in “Fertility and Sterility” Low and ultralow doses of flutamide can cause liver damage in young women with high androgen levels, regardless of dose or birth control use, with higher risk for those with higher BMI and liver enzyme levels before treatment.
March 2016 in “Journal of the Turkish-German Gynecological Association” The woman likely has a hormonal imbalance causing excessive hair growth.
January 2001 in “Chinese Journal of Reparative and Reconstructive Surgery” EGF aids skin development and healing, while bFGF absence in embryos may allow scar-free healing.
49 citations
,
August 2003 in “Journal of The American Academy of Dermatology” Higher IGF-1 levels in hair follicles link to better finasteride results for hair loss.
March 2017 in “European Urology Supplements” Gene differences affect finasteride side effects in men with hair loss.
6 citations
,
March 2024 in “Journal of Clinical Laboratory Analysis” Certain genetic variations in IGF2BP2 and IGFBP3 are linked to a higher risk of PCOS.
2 citations
,
May 2020 in “JAAD case reports” Ruxolitinib can cause a delayed skin reaction on the nose.
1 citations
,
February 2021 in “Scholars international journal of anatomy and physiology” Different forms of FGF5 either promote or inhibit hair growth.
November 2023 in “Journal of Skin and Sexually Transmitted Diseases” Gefitinib can cause scalp skin issues and permanent hair loss.